Skip to main content
INCY
NASDAQ Industrial Applications And Services

Incyte Q2 Revenue Surges 38% to $1.67B, Raises 2026 Guidance on Broad Product Strength

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$118.5
Mkt Cap
$23.748B
52W Low
$69.695
52W High
$120.71
52W Position info
70% above low
Off High info
1.8% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

INCY sits 70% above its 52-week low of $69.695.

Summary

Incyte reported Q2 2026 revenue of $1.67 billion, up 38% year-over-year, and raised full-year 2026 guidance on broad-based product growth and pipeline progress.

Updates

  1. · SEC 10-Q — Q2 net income was $585.6 million, or $2.81 diluted EPS, with six-month net income of $888.9 million. Cash and equivalents totaled $3.98 billion at June 30, 2026.

  2. · Reuters — Q2 adjusted EPS was $3.09, beating the $2.10 consensus. The company discontinued the INCB160058 blood cancer program.


Key Events · Earnings and Guidance · INCY

  • Q2 Revenue Hits $1.67B

    Total revenue grew 38% YoY to $1.67 billion, with total net sales up 40% to $1.49 billion. Jakafi/Jakafi XR net sales rose 7% to $817 million, Opzelura net sales surged 173% to $450 million (including a $246 million one-time CMS benefit), and the hematology/oncology portfolio jumped 69% to $222 million.

  • 2026 Guidance Raised Across Board

    Full-year total net sales guidance raised to $5.13-$5.26 billion (from $4.77-$4.94 billion). Opzelura net sales now seen at $1.05-$1.10 billion (from $750-$790 million), and hematology/oncology net sales at $860-$890 million (from $800-$880 million). Total GAAP R&D and SG&A expenses raised to $4.915-$4.995 billion, reflecting the Vega Therapeutics acquisition and incremental R&D investment.

  • Cash Position Strengthens to $4.5B

    Cash, cash equivalents and marketable securities totaled $4.5 billion as of June 30, 2026, up from $3.6 billion at year-end 2025, providing ample liquidity for pipeline investment and business development.

  • Pipeline Progress and Upcoming Catalysts

    Ten clinical data readouts expected in H2 2026, including four registrational trials. Key updates include Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa, plus multiple presentations at ESMO 2026.


Analysis · INCY · Industrial Applications And Services

A standout quarter saw total revenue jump 38% to $1.67 billion, fueled by robust demand across the entire commercial portfolio. Jakafi/Jakafi XR net sales grew 7% to $817 million, while Opzelura net sales more than doubled to $450 million, boosted by a one-time $246 million CMS settlement benefit. The hematology and oncology franchise surged 69% to $222 million, reflecting accelerating uptake of newer products like Niktimvo, Monjuvi, and Zynyz. Management raised full-year 2026 guidance across all key metrics, now expecting total net sales of $5.13-$5.26 billion, up from $4.77-$4.94 billion. The raised expense guidance incorporates the $1.25 billion Vega Therapeutics acquisition, adding a late-stage von Willebrand disease asset. With $4.5 billion in cash and ten data readouts expected in the second half, Incyte is well-capitalized to fund its pipeline while delivering top-line growth.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INCY was trading at $118.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23.7B. The 52-week trading range was $69.70 to $120.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INCY - Latest Insights

INCY
Oct 29, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $116.80
Real-time Price: $120.02 info
Change: +$3.22 (+3%) info
Market Cap: $24.658B info
INCY
Oct 29, 2026, 11:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $115.20
Real-time Price: $120.02 info
Change: +$4.82 (+4%) info
Market Cap: $24.658B info
INCY
Oct 29, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $117.76
Real-time Price: $120.02 info
Change: +$2.26 (+2%) info
Market Cap: $24.658B info
INCY
Aug 31, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $123.22
Real-time Price: $120.02 info
Change: -$3.20 (-3%) info
Market Cap: $24.658B info
INCY
Jul 29, 2026, 6:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $119.00
Real-time Price: $120.02 info
Change: +$1.02 (+0.86%) info
Market Cap: $24.658B info